Wall Street Zen Downgrades Regencell Bioscience (NASDAQ:RGC) to Sell

Regencell Bioscience (NASDAQ:RGC) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Regencell Bioscience presently has an average rating of “Sell”.

Regencell Bioscience Stock Performance

Shares of Regencell Bioscience stock opened at $5.02 on Friday. Regencell Bioscience has a 52-week low of $4.51 and a 52-week high of $69.00. The stock has a 50-day simple moving average of $16.25 and a 200-day simple moving average of $24.13.

Regencell Bioscience (NASDAQ:RGC) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.00) EPS for the quarter.

Institutional Trading of Regencell Bioscience

Several large investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP acquired a new position in shares of Regencell Bioscience during the 4th quarter valued at about $92,000. Amundi acquired a new stake in Regencell Bioscience in the 1st quarter worth approximately $219,000. Hudson Bay Capital Management LP acquired a new stake in Regencell Bioscience in the 4th quarter worth approximately $275,000. Bank of America Corp DE boosted its position in Regencell Bioscience by 59,113.8% during the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after purchasing an additional 17,143 shares during the period. Finally, XTX Topco Ltd bought a new stake in Regencell Bioscience during the third quarter worth approximately $598,000. Institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.